Fig. 81 (abstract P383).From: 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part twoTBRI Inhibition Augments anti-PD-1 Antibody Therapy in a Stroma-poor BRAF(V600E)-PTEN−/− Transplant Model of Melanoma that is Reversed with MAF Co-Transplantation. A. Anti-PD-1 and Anti-CTLA-4 antibody therapy in combination with TGFBi in a cell line-derived transplant model of BRAF(V600E)PTEN−/− melanoma. B. Co-transplantation of MAFs with the BRAF(V600E)PTEN−/− melanoma cell line suppresses the efficacy of anti-PD-1 antibody therapyBack to article page